recent
year
preval
chronic
infect
virus
human
immunodefici
viru
hiv
hepat
b
c
virus
hbv
hcv
respect
steadili
increas
new
virus
like
sever
acut
respiratori
syndrom
sar
coronaviru
emerg
thu
demand
effici
antivir
treatment
obviou
current
approxim
small
molecular
compound
approv
treat
viral
infect
least
half
intend
patient
hiv
infect
de
clercq
promin
class
drug
use
inhibit
viral
propag
group
inhibitor
dna
rna
synthesi
mani
nucleosid
analog
substanc
howev
fulli
specif
viral
polymeras
caus
sever
side
effect
upon
longterm
treatment
numer
viral
infect
effect
therapi
lack
altogeth
strategi
fast
develop
specif
antivir
agent
therefor
desir
antisens
strategi
employ
oligonucleotid
on
complementari
given
target
rna
offer
opportun
fulfil
demand
develop
antivir
compound
soon
sequenc
viru
known
fact
first
studi
publish
describ
use
inhibit
replic
roussarcoma
viru
zamecnik
stephenson
follow
section
deal
use
on
ribozym
small
interf
si
rna
antivir
agent
aptam
address
although
doubt
use
diagnos
treat
viral
infect
eg
darfeuil
et
al
de
beuckela
et
al
overview
mcknight
heinz
type
dealt
chapter
hu
et
al
menger
et
al
sprinzl
et
al
h
ulrich
ak
deisingh
present
volum
on
typic
nucleotid
length
bind
cognat
rna
via
watsoncrick
base
pair
sinc
dna
sequenc
length
statisti
fig
comparison
mechan
gene
silenc
on
sirna
on
left
exert
effect
predominantli
nucleu
wherea
sirna
work
mainli
cytoplasm
right
left
transport
nucleu
basepair
complementari
sequenc
mrna
rnase
h
recruit
hybrid
helix
cleav
rna
moieti
right
sirna
doubl
helix
reach
cytoplasm
one
strand
incorpor
protein
complex
call
risc
strand
discard
sirna
guid
risc
complementari
sequenc
target
rna
upon
bind
cleavag
target
molecul
induc
risc
go
multipl
round
cleavag
calli
occur
human
genom
target
rna
consid
highli
specif
receptor
agent
on
known
act
two
distinct
mechan
cell
nucleu
heteroduplex
dna
bound
rna
recogn
rnase
h
cleav
rna
moieti
hybrid
fig
rna
fragment
degrad
exonucleas
wherea
set
free
bind
new
rna
molecul
multipl
turnov
manner
cytoplasm
on
disabl
messeng
rna
prevent
protein
synthesi
steric
blockad
ribosom
theoret
on
direct
region
target
rna
practic
howev
long
rna
molecul
known
form
complex
secondari
tertiari
structur
furthermor
variou
protein
bind
rna
molecul
preclud
on
hybrid
therefor
necessari
select
region
target
rna
access
variou
method
develop
purpos
summar
review
sohail
southern
anoth
major
decis
develop
choic
suitabl
chemistri
ie
nucleotid
modif
unprotect
dna
on
degrad
blood
serum
within
hour
therefor
chemic
modifi
build
block
often
use
on
wide
employ
dna
analog
phosphorothio
one
nonbridg
oxygen
atom
phosphodiest
bond
replac
sulfur
atom
fig
on
consist
phosphorothio
combin
sever
advantag
includ
enhanc
nucleas
resist
activ
rnase
h
cleavag
eckstein
major
disadvantag
howev
decreas
bind
affin
complementari
sequenc
compar
isosequenti
dna
molecul
unintend
propens
interact
variou
protein
although
bind
plasma
protein
improv
pharmacokinet
profil
increas
serum
halflif
interact
protein
may
disadvantag
result
toxic
side
effect
observ
higher
dose
phosphorothio
appli
levin
due
problem
associ
phosphorothio
type
modif
develop
nucleotid
second
gener
carri
methyl
methoxyethyl
group
oxygen
ribos
fig
recent
year
numer
nucleic
acid
analog
develop
applic
technolog
kurreck
type
alter
rang
substitut
function
group
ribos
fluoroor
aminogroup
bior
tricycl
nucleotid
complet
replac
ribosephosph
backbon
peptid
bond
nucleotid
less
toxic
higher
target
affin
phosphorothio
lack
abil
induc
rnase
h
cleavag
complementari
mrna
therefor
socal
gapmer
develop
consist
modifi
nucleotid
end
protect
exonucleas
central
stretch
dna
phosphorothio
monom
suffici
activ
rnase
h
due
favor
properti
lock
nucleic
acid
lna
fig
increasingli
use
applic
recent
year
jepsen
wengel
chapter
kauppinen
et
al
volum
gapmer
consist
lna
dna
monom
center
found
exhibit
desir
properti
like
improv
nucleas
stabil
enhanc
target
affin
kurreck
fig
modifi
nucleotid
wide
use
antisens
approach
et
al
result
almost
higher
potenc
compar
isosequenti
dna
grunwel
et
al
import
hurdl
overcom
success
applic
cellular
uptak
on
dna
highli
charg
molecul
cross
hydrophob
membran
effici
therefor
transfect
agent
employ
facilit
entri
on
cell
wide
use
reagent
lipid
posit
charg
headgroup
neutral
neg
charg
on
onliposom
complex
thought
taken
endocytosi
intracellular
releas
on
facilit
addit
helper
lipid
interfer
endosom
membran
detail
use
cation
lipid
well
type
transfect
agent
describ
recent
overview
seksek
bolard
major
advantag
on
gener
applic
direct
virtual
rna
interest
virus
rna
genom
particularli
well
suit
target
on
sinc
mrna
also
genom
rna
attack
least
theoret
complet
viru
clearanc
achiev
contrast
dna
virus
retrovirus
provir
dna
stabli
integr
host
genom
mrna
newli
synthes
genom
rna
latter
case
target
on
thu
inhibit
viru
spread
expect
continu
treatment
requir
nevertheless
on
success
appli
inhibit
mani
virus
high
medic
relev
mcknight
heinz
due
space
restraint
recent
exampl
discuss
demonstr
potenti
on
treat
viru
replic
infect
hcv
major
health
problem
worldwid
chronic
infect
plusstrand
rna
viru
caus
liver
cirrhosi
liver
failur
hepatocellular
carcinoma
often
lead
requir
liver
transplant
sinc
current
treatment
hcv
unsatisfactori
need
new
specif
antihcv
drug
stand
reason
on
therefor
wide
use
intent
inhibit
hcv
replic
untransl
region
utr
one
highli
conserv
region
hcv
genom
frequent
target
on
sinc
region
strongli
structur
intens
effort
made
identifi
access
target
site
entir
viral
cycl
hcv
cytoplasm
thu
on
necessarili
need
design
activ
rnase
h
mainli
locat
nucleu
rather
shown
on
interf
assembl
translat
initi
complex
intern
ribosom
entri
site
ire
inhibit
translat
viral
polyprotein
cellfre
translat
assay
transfect
hepatoma
cell
line
detail
applic
onbas
strategi
inhibit
hcv
given
review
martinandmari
et
al
million
infect
individu
worldwid
hiv
one
sever
caus
infecti
diseas
although
half
substanc
approv
treatment
viral
infect
intend
treat
hiv
infect
still
urgent
need
new
therapeut
approach
current
drug
expens
patient
poor
countri
also
exert
sever
side
effect
upon
longterm
treatment
becom
ineffect
due
emerg
resist
mutant
numer
effort
prevent
hiv
replic
inhibitori
on
publish
review
see
jing
xu
recent
exampl
given
describ
hcv
antihiv
on
necessarili
requir
induc
viru
rna
degrad
rnase
h
may
well
employ
inhibit
essenti
process
viral
lifecycl
steric
block
exampl
arzumanov
et
al
develop
on
transactiv
respons
region
tar
stemloop
interact
transactiv
protein
tat
steric
blockad
interact
chimer
omethyl
rnalna
prevent
fulllength
hiv
transcript
anoth
studi
dimer
initi
site
chosen
target
on
et
al
lnadna
mixmer
direct
region
prevent
dimer
genom
inhibit
replic
clinic
isol
human
cell
line
work
differ
class
virus
yuan
et
al
recent
describ
inhibit
coxsackieviru
replic
cardiomyocyt
mous
heart
member
plusstrand
picornaviru
famili
infect
multipl
organ
human
consid
one
major
caus
viral
myocard
may
develop
dilat
cardiomyopathi
eventu
lead
heart
failur
specif
antivir
treatment
exist
import
pathogen
date
author
found
on
target
proxim
terminu
utr
effect
inhibit
replic
cardiomyocyt
cell
line
antivir
activ
evalu
myocard
mous
model
signific
decreas
viral
replic
viru
titer
observ
exampl
given
well
numer
studi
demonstr
potenti
on
act
specif
antivir
agent
approach
particularli
appeal
diseas
satisfactori
specif
treatment
avail
therefor
surpris
rather
high
percentag
on
current
test
clinic
trial
intend
treat
patient
viral
infect
approxim
on
reach
stage
clinic
test
one
drug
current
market
comprehens
overview
given
crook
focu
on
direct
viral
target
tabl
isi
pharmaceut
work
phosphorothio
biotech
exert
strang
advers
effect
phase
trial
like
due
cation
liposom
formul
use
deliveri
system
hybridon
develop
secondgener
on
target
gag
gene
mrna
protein
human
papillomaviru
mbi
phase
trial
on
show
promis
safeti
result
confirm
possibl
secondgener
on
deliv
oral
on
test
patient
hbv
hcv
infect
cpg
cpg
coley
pharmaceut
dynavax
technolog
mechan
action
latter
on
thought
activ
immun
respons
via
tolllik
receptor
recogn
cpg
motiv
rather
classic
mechan
agraw
kandimalla
first
drug
approv
us
food
drug
administr
fda
phosphorothio
name
vitraven
fomivirsen
antivir
target
rna
immediateearli
mrna
human
cytomegaloviru
cmv
mrna
intend
treat
cmvinduc
retin
immunodefici
patient
acquir
immunodefici
syndrom
aid
major
drawback
drug
mode
applic
sinc
must
inject
intravitr
although
vitraven
meet
import
need
affect
patient
minor
commerci
signific
late
second
onbas
drug
approv
fda
macugen
aptam
target
vascular
endotheli
growth
factor
vegf
provid
antiangiogen
treatment
patient
wet
form
agerel
macular
degener
eye
diseas
lead
loss
central
vision
earli
research
group
thoma
cech
sidney
altman
discov
rna
molecul
possess
catalyt
activ
absenc
protein
moieti
ribonucl
acid
enzymat
properti
name
ribozym
meanwhil
sever
class
ribozym
identifi
roughli
divid
larg
ribozym
consist
sever
hundr
thousand
nucleotid
small
ribozym
rang
nucleotid
length
doudna
cech
addit
fascin
object
basic
research
ribozym
employ
medic
purpos
review
see
sulleng
gilboa
focu
use
ribozym
antivir
agent
hammerhead
hairpin
ribozym
intens
studi
wide
use
ribozym
date
class
origin
isol
plant
pathogen
applic
molecular
tool
becam
possibl
develop
variant
capabl
cleav
target
rna
multipl
turnov
manner
secondari
structur
hammerhead
ribozym
target
tat
gene
hairpin
ribozym
direct
site
long
termin
repeat
depict
fig
b
respect
describ
on
ribozym
bind
specif
target
rna
watsoncrick
base
pair
addit
possess
capabl
cleav
complementari
rna
molecul
without
aid
cellular
protein
ngok
et
al
b
hairpin
ribozym
engin
cleav
site
long
termin
repeat
ojwang
et
al
c
dnazym
consensu
sequenc
utr
picornavirus
schubert
et
al
optim
dnazym
contain
omethyl
rna
monom
underlin
posit
arrow
indic
cleavag
site
challeng
face
develop
therapeut
ribozym
similar
optim
effici
on
addit
difficulti
met
first
suitabl
target
site
identifi
region
access
ribozym
employ
addit
fulfil
certain
sequenc
requir
effici
cleavag
ribozym
exampl
hammerhead
ribozym
cleav
prefer
aug
guc
triplet
wherea
dnazym
describ
process
junction
purin
pyrimidin
second
import
step
stabil
ribozym
sinc
rna
molecul
even
suscept
nucleolyt
degrad
dna
on
task
complic
fact
introduct
modifi
nucleotid
often
lead
sever
loss
catalyt
activ
beigelman
colleagu
perform
systemat
optim
studi
hammerhead
ribozym
develop
design
modifi
nucleotid
posit
except
five
essenti
ribonucleotid
molecul
retain
high
catalyt
activ
display
serum
halflif
day
also
use
clinic
trial
describ
sect
date
catalyt
activ
on
compos
rna
discov
natur
enzymat
dna
on
refer
dnazym
dna
enzym
deoxyribozym
howev
obtain
vitro
select
sinc
expect
stabl
nucleas
promin
repres
class
molecul
socal
dnazym
santoro
joyc
secondari
structur
shown
fig
although
catalyt
activ
on
consist
dna
higher
intrins
resist
nucleolyt
degrad
still
need
protect
applic
biolog
system
systemat
improv
properti
dnazym
target
utr
human
rhinoviru
schubert
et
al
result
dnazym
contain
modifi
nucleotid
underlin
termini
catalyt
core
depict
fig
display
tenfold
increas
catalyt
activ
multipl
turnov
condit
substanti
improv
resist
endoand
exonucleas
dnazym
direct
consensu
sequenc
picornavirus
occur
rhinoviru
also
variou
polio
echo
entero
coxsackievirus
surprisingli
unmodifi
dnazym
cleav
rhinoviru
rna
reason
rate
incap
cleav
coxsackieviru
rna
despit
full
sequenc
homolog
similar
overal
structur
introduct
nucleotid
high
target
affin
omethyl
rna
lna
howev
dnazym
regain
capabl
cleav
coxsackieviru
rna
high
catalyt
turnov
rate
success
compet
local
structur
target
rna
modifi
dnazym
use
degrad
broad
rang
picornaviru
rna
furthermor
demonstr
strategi
introduc
nucleotid
high
target
affin
may
gener
applic
cleav
seemingli
unsuit
target
site
describ
on
cellular
uptak
ribozym
deoxyribozym
enhanc
use
transfect
reagent
ribozym
howev
exogen
appli
chemic
presynthes
molecul
also
encod
plasmid
express
endogen
open
road
use
viral
vector
employ
gene
therapeut
purpos
eg
retrovirus
adenovirus
adenoassoci
virus
ribozym
deoxyribozym
wide
use
inhibit
viru
replic
cell
cultur
vivo
exampl
discuss
comprehens
overview
recent
given
peracchi
earli
variou
region
target
hammerhead
hairpin
ribozym
eg
zhou
et
al
ojwang
et
al
meanwhil
protect
effect
ribozym
infect
also
demonstr
vivo
scidhu
mous
model
hematopoiet
progenitor
cell
transduc
tatrev
env
hammerhead
ribozym
well
rev
aptam
significantli
protect
infect
upon
challeng
bai
et
al
dnazym
also
success
employ
inhibit
either
directli
target
viral
rna
zhang
et
al
prevent
viru
entri
downregul
coreceptor
goila
banerjea
addit
hepat
b
c
virus
major
target
antivir
ribozym
exampl
chemic
stabil
hammerhead
ribozym
design
target
highli
conserv
utr
hcv
cell
cultur
inhibit
replic
hcvpolioviru
chimera
macejak
et
al
ribozym
dub
heptazym
subsequ
employ
clinic
trial
outlin
differ
approach
develop
gener
ribozym
target
hbv
express
tripleribozym
cassett
undergo
intracellular
selfprocess
pan
et
al
sophist
construct
suitabl
reduc
viral
dna
liver
transgen
mice
greater
measur
week
infect
furthermor
dnazym
contain
phosphoroamid
nucleotid
capabl
inhibit
replic
influenza
virus
takahashi
et
al
sever
ribozym
alreadi
test
clinic
trial
summar
sulleng
gilboa
studi
intend
treat
viral
infect
ribozym
use
attempt
inhibit
cancer
growth
clinic
trial
ribozym
either
express
intracellularli
vector
deliv
chemic
presynthes
on
first
phase
clinic
trial
mid
conduct
retrovir
vector
deliv
hammerhead
hairpin
ribozym
target
rna
lymphocyt
hematopoiet
precursor
cell
isol
infect
individu
healthi
twin
treat
ribozym
vector
ex
vivo
select
expans
transduc
cell
infus
bloodstream
infect
patient
treatment
suppos
increas
resist
hematopoiet
cell
spread
viru
although
procedur
found
safe
ribozym
express
transduc
cell
could
detect
durat
protect
effect
unsatisfactori
therefor
necessari
develop
improv
method
transduc
pluripot
hematopoiet
stem
cell
order
achiev
longterm
resist
hiv
michienzi
et
al
addit
studi
treat
patient
hiv
infect
one
clinic
trial
initi
hammerhead
ribozym
target
hcv
contrast
trial
describ
preced
paragraph
viral
vector
employ
deliv
ribozym
aforement
chemic
presynthes
ribozym
heptazym
use
test
usman
blatt
encourag
result
initi
clinic
studi
led
initi
phase
ii
trial
heptazym
alon
combin
interferon
ifn
find
hcv
rna
level
serum
patient
treat
ribozym
reduc
along
result
toxolog
studi
led
decis
stop
clinic
experiment
heptazym
peracchi
taken
togeth
ribozym
treat
viral
infect
cancer
well
toler
clinic
set
therapeut
effici
rather
low
recent
find
indic
minim
ribozym
variant
use
trial
lack
sequenc
element
essenti
high
catalyt
activ
physiolog
condit
khvorova
et
al
sinc
new
techniqu
believ
much
effici
emerg
discoveri
rna
interfer
rnai
approach
develop
rnabas
therapeut
switch
use
sirna
rather
ribozym
rnai
denot
disrupt
rna
molecul
induc
doublestrand
ds
rna
sequenc
process
first
identifi
nematod
caenorhabd
elegan
fire
et
al
subsequ
work
elucid
biochem
basi
underli
mechan
recent
review
see
meister
tuschl
long
dsrna
cut
rnase
iiityp
endonucleas
term
dicer
result
rna
duplex
symmetr
twonucleotid
overhang
end
known
small
interf
rna
sirna
one
strand
prefer
strand
subsequ
incorpor
proteinac
complex
call
rnainduc
silenc
complex
risc
whose
exact
composit
still
investig
rna
strand
program
risc
act
specif
rna
complementari
sequenc
target
molecul
bound
cleav
center
target
sequenc
afterward
damag
rna
molecul
quickli
degrad
cellular
nucleas
risc
go
sever
round
cleavag
haley
zamor
contrast
rnase
hmediat
cleavag
induc
on
process
take
place
predominantli
cytoplasm
fig
overal
mechan
gene
silenc
mediat
dsrna
conserv
virtual
eukaryot
mammal
howev
presenc
dsrna
exceed
bp
cytoplasm
initi
innat
ifn
immun
respons
result
extens
cell
death
unspecif
reaction
hamper
use
rnai
mammalian
cell
avoid
sirna
molecul
employ
elbashir
et
al
sirna
shown
extrem
potent
inhibitor
target
gene
express
eg
grunwel
et
al
meanwhil
use
knock
plethora
individu
gene
cell
cultur
experi
order
investig
gene
function
trace
molecular
pathway
silva
et
al
rnai
also
appli
mous
model
human
diseas
summar
sioud
chapter
sioud
volum
comprehens
overview
current
statu
applic
rnai
method
given
numer
recent
review
eg
mittal
dorsett
tuschl
target
degrad
rna
molecul
trigger
sirna
multistep
process
least
two
factor
critic
efficaci
sirna
structur
assembl
rnai
enzym
complex
risc
shown
depend
thermodynam
characterist
sirna
respect
rel
stabil
end
duplex
khvorova
et
al
schwarz
et
al
base
find
sever
algorithm
develop
predict
effici
sirna
eg
reynold
et
al
access
target
sequenc
other
observ
even
welldesign
sirna
excel
thermodynam
featur
may
show
silenc
activ
target
region
sequest
stabl
intern
structur
kretschmerkazemi
far
sczakiel
schubert
et
al
exampl
target
utr
picornavirus
turn
particularli
ineffici
schubert
et
al
phipp
et
al
saleh
et
al
region
known
highli
structur
associ
cellular
viral
protein
possibl
preclud
sirna
hybrid
similarli
viral
rna
speci
found
resist
degrad
rnai
sirna
direct
rotaviru
respiratori
syncyti
viru
afford
degrad
mrna
speci
virus
interfer
viral
genom
rna
sequenc
bitko
barik
aria
et
al
hu
et
al
observ
like
due
extens
associ
viral
genom
rna
protein
local
compart
inaccess
risc
look
back
year
effort
deliveri
ribozym
on
research
today
benefit
rich
bodi
experi
regard
transfer
cell
see
seksek
bollard
review
similar
ribozym
sirna
deliv
presynthes
dsrna
molecul
express
intracellularli
plasmid
transfect
effici
presynthes
sirna
usual
quit
high
standard
cell
line
silenc
effect
wear
matter
day
intracellular
concentr
sirna
decreas
due
cell
divis
degrad
cellular
nucleas
addit
sirna
modifi
chemic
increas
nucleas
resist
bodi
fluid
achiev
longer
last
knockdown
plasmid
vector
design
afford
continu
express
short
hairpin
sh
rna
intracellularli
process
give
sirna
fig
mittal
use
plasmid
vector
allow
select
stabli
transfect
cell
shown
exert
genesilenc
activ
even
month
vector
deliveri
brummelkamp
et
al
deliveri
plasmid
dna
use
standard
transfect
protocol
howev
often
unsatisfactori
particularli
primari
cell
stem
cell
concern
effici
uptak
achiev
exploit
natur
abil
virus
infect
host
cell
oncovirus
lentivirus
adenovirus
recombin
adenoassoci
virus
viral
class
often
employ
shuttl
deliveri
transgen
cell
excel
fig
vector
express
sirna
first
step
selfcomplementari
rna
name
short
hairpin
rna
shrna
express
control
polymeras
iii
promot
shrna
subsequ
process
give
sirna
endonucleas
dicer
sirna
doubl
express
sidex
vector
employ
express
two
shrna
direct
differ
site
target
rna
simultan
schubert
et
al
thu
mutat
one
target
site
lead
abrog
silenc
compens
unalt
effici
second
sirna
detail
see
text
lent
comprehens
overview
viral
deliveri
system
given
paper
thoma
et
al
system
deliveri
mice
usual
perform
inject
sirna
tail
vein
larg
volum
liquid
use
high
pressur
method
term
hydrodynam
tail
vein
inject
fig
sirna
subsequ
found
enrich
liver
highpressur
inject
howev
applic
human
subtl
way
system
administr
need
sought
one
promis
report
yet
come
alnylam
pharmaceut
studi
sirna
conjug
cholesterol
molecul
construct
substanti
improv
pharmacokinet
properti
effici
reduc
plasma
level
endogen
apolipoprotein
b
mice
intraven
administr
soutschek
et
al
sirna
consid
highli
specif
molecular
tool
capac
discrimin
mismatch
seem
depend
sirna
sequenc
posit
mismatch
nucleotid
unspecif
effect
sirna
describ
sever
report
semizarov
et
al
found
induct
gene
relat
stress
apoptosi
higher
sirna
concentr
fig
hydrodynam
tail
vein
inject
sirna
rapidli
inject
tail
vein
mice
larg
volum
fluid
sirna
accumul
preferenti
liver
offtarget
effect
detect
express
profil
induct
ifn
respons
shrna
sirna
also
report
jackson
et
al
bridg
et
al
sledz
et
al
moreov
sirna
shown
inhibit
translat
partial
complementari
mrna
molecul
imperfect
hybrid
micrornalik
manner
doench
sharp
scacheri
et
al
sirna
partial
complementar
one
human
gene
thu
prone
unintend
gene
silenc
therefor
advis
employ
highli
effici
sirna
low
dose
yield
suffici
result
side
effect
expect
minim
discuss
relev
issu
concern
effici
specif
rnai
approach
see
hannon
rossi
virus
often
elud
longterm
inhibit
acquir
mutat
render
antivir
compound
ineffect
problem
observ
rnai
approach
sustain
inhibit
polioviru
gitlin
et
al
boden
et
al
da
et
al
although
sirna
employ
studi
inhibit
viral
propag
initi
viru
titer
increas
upon
prolong
incub
analysi
resist
mutant
reveal
either
point
mutat
target
region
extens
rearrang
viral
rna
sever
strategi
may
use
prevent
enrich
escap
mutant
one
target
conserv
sequenc
less
like
yield
viabl
viru
mutat
anoth
reduc
level
host
cellular
gene
necessari
viral
entri
propag
led
substanti
reduct
viru
titer
novina
et
al
cellular
gene
less
prone
mutat
therefor
less
like
allow
viral
escap
silenc
pursu
approach
howev
risk
sideeffect
must
obvious
address
thoroughli
analog
convent
combin
therapi
third
strategi
prevent
escapemut
enrich
involv
two
sirna
use
simultan
recent
describ
sirna
doubl
express
vector
sidex
contain
gene
two
differ
sirna
target
rnadepend
rna
polymeras
coxsackieviru
schubert
et
al
fig
even
artifici
point
mutat
introduc
target
gene
respect
monoexpress
vector
longer
capabl
silenc
doubl
express
vector
maintain
high
silenc
activ
although
find
deleteri
effect
simultan
use
two
sirna
observ
differ
sirna
present
one
cell
may
compet
access
rnai
machineri
bitko
et
al
thu
effici
one
sirna
may
compromis
due
presenc
second
speci
anoth
difficulti
prevent
viral
escap
may
amount
viral
particl
present
blood
patient
state
viremia
hcv
infect
virion
per
millilit
may
present
bloodstream
even
reduct
titer
may
still
leav
enough
viru
particl
intact
allow
escap
highest
effici
knockdown
therefor
even
desir
vast
bodi
studi
report
employ
rnai
antivir
purpos
mammalian
cell
alreadi
publish
extent
inhibit
viral
propag
measur
studi
depend
sever
factor
choic
cell
line
virul
titer
viru
strain
sirna
deliveri
method
time
infect
sirna
deliveri
time
method
readout
detect
thu
difficult
make
quantit
comparison
studi
draw
conclus
possibl
clinic
util
individu
compound
cellcultur
experi
follow
paragraph
studi
discuss
like
lead
clinic
applic
nearer
futur
awar
fact
select
bias
comprehens
overview
class
virus
target
rnai
provid
paper
haasnoot
et
al
ryther
et
al
influenza
major
threat
societi
worldwid
least
million
peopl
die
catastroph
outbreak
viru
influenza
virus
envelop
singlestrand
rna
virus
whose
genom
segment
eight
part
neg
polar
notori
chang
outward
shape
due
small
mutat
princip
antigen
thu
viru
may
escap
protect
immun
induc
previous
preval
viral
strain
vaccin
provid
effect
protect
influenza
viru
infect
older
immunocompromis
peopl
howev
vaccin
efficaci
rather
limit
recent
warn
threat
influenza
pandem
discuss
news
focu
enserink
ge
colleagu
test
antivir
effect
sirna
direct
conserv
region
influenza
viru
cell
cultur
embryon
chicken
egg
three
sirna
potent
inhibitor
viral
propag
one
sirna
reduc
level
specif
target
mrna
two
other
result
reduc
level
viral
rna
speci
author
conclud
target
protein
critic
role
viral
transcript
replic
year
later
success
applic
previous
identifi
sirna
mice
report
two
studi
tompkin
cowork
administ
sirna
hydrodynam
tail
vein
inject
follow
viral
infect
h
later
day
viru
titer
lung
lower
mice
receiv
unrel
control
sirna
day
post
challeng
anim
treat
control
sirna
die
wherea
mortal
reduc
sirnatr
anim
combin
sirna
yield
surviv
second
studi
sirna
administ
complex
polyethyleneimin
pei
intraven
inject
method
compat
use
human
ge
et
al
peicomplex
nucleic
acid
found
predominantli
lung
reduct
viru
titer
h
infect
approxim
tenfold
even
sirna
administ
h
infect
also
plasmid
dna
code
shrna
found
inhibit
viral
propag
mice
administ
intraven
complex
pei
instil
lung
recent
intranas
administr
sirna
lung
report
two
group
bitko
et
al
zhang
et
al
sirna
direct
differ
region
respiratori
syncyti
viru
rsv
major
respiratori
pathogen
famili
paramyxovirida
contain
nonseg
strand
rna
genom
barik
nmol
effici
sirna
administ
intranas
without
transfect
agent
viral
titer
reduc
lung
mice
three
order
magnitud
addit
sirnatr
mice
show
sign
respiratori
distress
week
observ
use
ongo
infect
antivir
effect
decreas
remain
clearli
visibl
even
sirna
given
day
viral
challeng
sirna
appli
zhang
cowork
direct
viral
gene
antagon
signal
host
shrnaexpress
plasmid
complex
nanochitosan
natur
biodegrad
polym
deliv
day
viral
inocul
express
lung
diminish
h
later
wherea
viral
gene
remain
unaffect
observ
lend
proof
find
discuss
name
viral
genom
rna
may
inaccess
rnai
level
lung
tissu
mice
significantli
increas
anim
receiv
shrna
infect
treatment
sirna
day
infect
still
reduc
viru
titer
lung
moreov
mice
treat
shrna
day
infect
show
substanti
decreas
lung
inflamm
compar
control
mice
hbv
partial
doublestrand
dna
viru
hepadnavirida
famili
primarili
infect
liver
although
effici
vaccin
avail
estim
one
million
peopl
die
everi
year
hbvrelat
diseas
number
carrier
lay
around
million
chronic
infect
give
rise
liver
cirrhosi
hepatocellular
carcinoma
enter
cell
viral
genom
transport
nucleu
four
rna
speci
transcrib
export
cytoplasm
one
transcript
refer
pregenom
rna
also
serv
templat
revers
transcript
rnai
target
viral
circular
dsdna
resid
cell
nuclei
chronic
infect
patient
interfer
one
mrna
speci
report
repeatedli
replic
hbv
support
anim
therefor
replicationcompet
plasmid
develop
mimic
step
viral
life
cycl
cell
cultur
small
anim
one
first
report
function
antivir
rnai
mammal
mccaffrey
colleagu
coinject
shrna
express
vector
plasmid
contain
hbv
replicon
tail
vein
mice
use
hydrodynam
transfect
day
liver
anim
probe
replic
genom
viral
dna
rna
transcript
northern
southern
blot
shrna
significantli
reduc
level
hbv
rna
dna
also
amount
hbv
surfac
antigen
hbsag
serum
decreas
use
effect
shrna
investig
addit
howev
two
unexplain
observ
report
shrna
direct
site
present
longest
four
mrna
found
reduc
level
target
mrna
also
level
viral
transcript
treatment
shrna
includ
unrel
control
shift
balanc
singlestrand
doublestrand
genom
dna
toward
singlestrand
form
data
rais
possibl
shrna
may
sequenceindepend
antivir
effect
whose
mechan
unknown
yet
chemic
synthes
sirna
employ
klein
cowork
tail
vein
inject
togeth
replicationcompet
hbv
plasmid
sirna
inhibit
express
target
protein
liver
mice
effect
one
sirna
sustain
least
day
inhibit
second
sirna
ceas
around
day
uprichard
cowork
succeed
clear
preexist
hbv
gene
express
liver
mice
antigen
level
serum
rna
express
presenc
replic
dna
intermedi
significantli
reduc
transgen
mice
contain
hbvplasmid
shrnaexpress
vector
administ
hydrodynam
tail
vein
inject
recombin
adenovirus
antivir
effect
sustain
least
day
interestingli
studi
level
rna
somewhat
less
reduc
level
transcript
although
speci
contain
target
site
reason
observ
lend
specul
anoth
major
hepat
pathogen
hcv
see
also
easili
grown
cell
cultur
reason
plasmid
replicon
contain
subgenom
fragment
whole
genom
hcv
use
show
gener
applic
antivir
rnai
approach
mice
mccaffrey
colleagu
use
highpressur
tail
vein
inject
deliv
plasmid
express
fusion
construct
luciferas
viral
protein
liver
mice
sirna
shrnaexpress
plasmid
cotransfect
report
plasmid
reduct
luciferas
express
whole
bodi
anim
measur
respect
sever
group
report
sirna
direct
differ
region
mrna
hcv
reduc
viral
rna
protein
level
list
see
radhakrishnan
et
al
randal
rice
randal
colleagu
found
greater
inhibit
rna
level
transfect
effici
sirna
decreas
may
caus
either
equal
reduct
hcv
rna
cell
complet
destruct
viral
rna
cell
use
immunofluoresc
techniqu
author
found
inde
almost
cell
complet
clear
hcv
protein
cell
howev
fluoresc
brightli
indic
detect
reduct
hcv
level
taken
place
achiev
sustain
inhibit
stabl
transfect
shrna
express
vector
perform
wilson
colleagu
found
reduct
hcvgene
express
cell
challeng
replicon
stabli
transfect
shrna
week
earlier
zhang
cowork
use
adenovir
deliveri
knock
cellular
target
indispens
hcv
replic
achiev
signific
reduct
hcvexpress
cell
greatest
bodi
work
regard
antivir
rnai
approach
perform
hiv
outlin
effort
alreadi
taken
inhibit
spread
devast
viru
mean
gene
therapi
employ
ribozym
rnai
prove
significantli
potent
ribozym
reduct
viru
titer
therefor
employ
shrnaexpress
vector
gene
therapi
set
valid
ribozym
may
boost
effici
approach
numer
sirna
shrna
direct
differ
region
hiv
rna
success
suppress
viral
gene
express
replic
see
eg
comprehens
list
given
haasnoot
et
al
hannon
rossi
earli
question
rais
step
viral
life
cycl
sirna
would
interfer
jacqu
colleagu
test
number
presynthes
sirna
plasmidexpress
shrna
viral
vif
nef
gene
well
long
termin
repeat
ltr
sirna
suppress
product
viral
particl
infecti
hiv
clone
author
also
found
dramat
inhibit
viral
genom
rna
complementari
c
dna
integr
dna
studi
conclud
sirna
employ
case
inhibit
viral
life
cycl
earli
stage
somewhat
differ
result
howev
present
hu
cowork
found
reduct
viral
cdna
cell
transfect
potent
sirna
viral
gag
pol
rna
coburn
cullen
use
sirna
tat
rev
notic
slight
decreas
provir
dna
product
seem
suffici
explain
massiv
drop
viral
gene
express
brought
sirna
extent
incom
viral
rna
access
rnai
thu
still
discuss
viral
escap
shown
major
problem
tri
inhibit
replic
see
sever
group
therefor
turn
silenc
cellular
gene
necessari
viral
propag
arteaga
et
al
qin
colleagu
transduc
lymphocyt
uninfect
individu
lentivir
vector
code
sirna
viral
coreceptor
tenfold
downregul
express
receptor
observ
led
protect
viral
challeng
may
suitabl
target
interfer
entri
essenti
normal
immun
function
eleg
method
target
deliveri
transgen
code
sirna
isol
hematopoiet
progenitor
cell
give
rise
hematopoiet
cell
capabl
infect
viru
cell
transduc
transgen
choic
reinfus
patient
banerjea
cowork
use
lentivir
vector
introduc
antirev
sirna
primari
hematopoiet
progenitor
cell
cell
subsequ
expand
scidhu
thyliv
graft
day
mice
sacrif
thymocyt
collect
one
anim
cell
posit
transgen
wherea
anoth
anim
show
posit
vivoderiv
thymocyt
posit
transgen
subsequ
enrich
challeng
sirnaexpress
thymocyt
show
signific
protect
viral
challeng
long
day
post
infect
signific
experi
obtain
antihiv
ribozym
high
relev
urgent
need
new
cheap
hivtherapeut
human
clinic
trial
employ
rnai
approach
virus
expect
begin
soon
hannon
rossi
research
focu
sirnainduc
inhibit
major
myocardi
pathogen
caus
sever
heart
muscl
infect
see
sect
opinion
particularli
well
suit
target
sirna
sinc
viru
cytoplasm
lifecycl
complet
viru
clearanc
rnai
expect
type
viru
viral
dna
genom
dna
intermedi
retrovirus
suscept
riscmedi
cleavag
fig
initi
experi
sirna
direct
utr
unsuccess
like
due
stabl
secondari
structur
region
viral
genom
subsequ
effort
target
rnadepend
rna
polymeras
sirna
howev
led
concentrationdepend
inhibit
viru
plaqu
assay
reveal
reduct
viru
propag
one
log
step
schubert
et
al
anoth
aspect
support
idea
use
rnai
approach
coxsackievirus
clinic
phase
ii
trial
et
al
demonstr
treatment
elimin
cardiotrop
virus
improv
left
ventricular
function
effect
sirna
specif
observ
induct
ifn
respons
sirna
sledz
et
al
undesir
side
effect
case
may
prove
benefici
applic
evalu
state
develop
rnai
techniqu
achiev
must
ask
long
take
first
drug
approv
act
mean
rnai
enthusiasm
novel
highli
effici
techniqu
skeptic
applic
balanc
time
expect
may
somewhat
limit
year
research
medic
applic
molecul
led
singl
approv
drug
minor
commerci
signific
one
approv
aptam
number
compani
like
alnylam
pharmaceut
benitec
intern
therapeut
cytrx
corpor
sirna
therapeut
nucleon
develop
sirna
treatment
viral
infect
hiv
hcv
hbv
accord
compani
respect
web
site
two
compani
sirna
therapeut
acuiti
pharmaceut
recent
initi
phase
clinic
studi
sirna
interf
vascular
treatment
agerel
macular
degener
result
studi
would
first
clinic
data
avail
sirna
may
allow
betterfound
predict
futur
rnai
therapeut
approach
on
valuabl
altern
low
molecular
weight
compound
treatment
viral
infect
on
ribozym
use
mani
year
inhibit
viru
replic
advanc
molecul
even
evalu
clinic
trial
approv
antisens
drug
date
antivir
despit
well
toler
dose
employ
on
ribozym
frequent
fail
provid
convinc
evid
therapeut
benefit
recent
develop
rnai
technolog
howev
like
overcom
problem
aforement
approach
due
higher
effici
three
half
year
initi
descript
gene
silenc
sirna
mammalian
cell
first
clinic
trial
base
principl
rnai
commenc
furthermor
sirna
cancer
viral
target
expect
enter
clinic
soon
one
major
problem
longterm
inhibit
virus
abil
escap
kind
treatment
due
high
mutat
rate
therefor
advantag
select
sequenc
viru
highli
conserv
addit
sever
distinct
region
viru
target
simultan
either
sirna
doubl
express
sidex
vector
schubert
et
al
combin
differ
type
antivir
agent
eg
ribozym
sirna
michienzi
et
al
principl
establish
on
antivir
agent
techniqu
offer
opportun
rapidli
develop
inhibitor
newli
discov
virus
variant
wellknown
virus
